5:53 PM
 | 
Nov 07, 2013
 |  BC Extra  |  Clinical News

Gazyva vs. rituximab PFS numbers unveiled

Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit provided detailed data on Thursday from the Phase III CLL11 (BO21004) trial evaluating the company's Gazyva obinutuzumab ( GA101) to treat previously untreated chronic lymphocytic leukemia (CLL). In Stage 2 of the trial, Gazyva plus chlorambucil chemotherapy led to a median progression-free survival (PFS), the primary endpoint, of 26.7 months vs....

Read the full 293 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >